Peter Harrison - Chief Executive Officer
Peter has worked in the field of antibody technology since 1986 and has extensive experience of the development and commercialisation of antibody technologies. He graduated in Natural Sciences from Clare College Cambridge in 1980 and joined the graduate training scheme at Shell Chemicals UK Ltd. In 1986 he joined Celltech Ltd to manage their contract antibody production business and in 1991 he joined KS Biomedix Ltd and helped to establish sheep monoclonal antibody technology at their Farnham research laboratory. Following the acquisition of KS Biomedix Limited by Xenova plc in 2003, he led a management buy-out that resulted in the formation of Bioventix and he has led the subsequent commercial development of the Company.
Ian Nicholson - Chairman and Independent Non-Executive Director
Ian was appointed as Non-Executive Chairman of Bioventix in November 2004. Ian is also a Non-executive Director of Clinigen Group plc, a specialty pharmaceuticals and services business and also an Operating Partner at Advent Life Sciences LLP. From 2013 to 2021 Ian was Chief Executive Officer of F2G Ltd an antifungal drug development company and from 2004 to 2012 Ian was Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company. He previously held the position of Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian is Chairman of the Audit Committee and is a member of the Remuneration Committee.
Nicholas McCooke - Independent Non-Executive Director
Nick was appointed as Non-Executive Director of Bioventix in 2014 when the Company first listed on AIM. Nick has worked in the biotech industry for over 30 years and is now an independent consultant providing operational, strategic and commercial advice and hands-on support to biotech companies. He has led several successful companies. He was the founding CEO of Solexa, the Cambridge University spin-out where he built the team that invented and developed Next Generation DNA sequencing. Subsequently he was CEO of Belgian company Pronota, which translated novel protein biomarkers into diagnostics, and where he gained much knowledge and expertise in the diagnostic development and market access process. Most recently he was CEO of DNA sequencing technology company Longas Technologies pty Ltd. He has an MBA from the London Business School. Nick is Chairman of the Remuneration Committee and Nomination Committee and is a member of the Audit Committee.
Bruce Hiscock - Chief Financial Officer
Bruce was appointed to the Board in 2020. He is a member of the Institute of Chartered Accountants of Scotland (ICAS) and was previously CEO and CFO of everyLIFE Technologies Limited, a technology business developing and delivering digital care planning SaaS solutions to social care providers. Prior to this he was the Managing Director of MITIE Security Systems Limited, the CEO of Protec plc, an AIM listed security and technology services business, and has held several CFO roles at both fast-growing listed and private companies over a 30-year career.